Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.

Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z.

Eur Urol. 2014 Apr;65(4):755-65. doi: 10.1016/j.eururo.2013.11.010. Epub 2013 Nov 18. Review.

PMID:
24275310
[PubMed - indexed for MEDLINE]
2.

Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.

Veenboer PW, Bosch JL.

J Urol. 2014 Apr;191(4):1003-8. doi: 10.1016/j.juro.2013.10.046. Epub 2013 Oct 16. Review.

PMID:
24140548
[PubMed - indexed for MEDLINE]
3.

Imidafenacin for the treatment of overactive bladder.

Leone Roberti Maggiore U, Scala C, Venturini PL, Ferrero S.

Expert Opin Pharmacother. 2013 Jul;14(10):1383-97. doi: 10.1517/14656566.2013.796930. Epub 2013 May 6. Review. Erratum in: Expert Opin Pharmacother. 2014 Feb;15(2):301.

PMID:
23641864
[PubMed - indexed for MEDLINE]
4.

Treatments for overactive bladder: focus on pharmacotherapy.

Geoffrion R.

J Obstet Gynaecol Can. 2012 Nov;34(11):1092-101.

PMID:
23231848
[PubMed - in process]
5.

Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.

Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, Venturini PL, Ferrero S.

Expert Opin Drug Metab Toxicol. 2012 Nov;8(11):1387-408. doi: 10.1517/17425255.2012.714365. Epub 2012 Aug 8. Review.

PMID:
22871042
[PubMed - indexed for MEDLINE]
6.

Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.

Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL.

Ann Intern Med. 2012 Jun 19;156(12):861-74, W301-10. doi: 10.7326/0003-4819-156-12-201206190-00436. Review.

PMID:
22711079
[PubMed - indexed for MEDLINE]
7.

Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?

Paquette A, Gou P, Tannenbaum C.

J Am Geriatr Soc. 2011 Jul;59(7):1332-9. doi: 10.1111/j.1532-5415.2011.03473.x. Epub 2011 Jun 30. Review.

PMID:
21718264
[PubMed - indexed for MEDLINE]
8.

Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.

Kessler TM, Bachmann LM, Minder C, L√∂hrer D, Umbehr M, Sch√ľnemann HJ, Kessels AG.

PLoS One. 2011 Feb 23;6(2):e16718. doi: 10.1371/journal.pone.0016718.

PMID:
21373193
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Drug Class Review: Agents for Overactive Bladder: Final Report Update 4 [Internet].

McDonagh MS, Selover D, Santa J, Thakurta S.

Portland (OR): Oregon Health & Science University; 2009 Mar.

PMID:
21089246
[PubMed]
Books & Documents
10.

Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.

Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B.

Dig Dis Sci. 2011 Jan;56(1):7-18. doi: 10.1007/s10620-010-1313-3. Epub 2010 Jul 2. Review.

PMID:
20596778
[PubMed - indexed for MEDLINE]
11.

Drug Class Review on Agents for Overactive Bladder: Final Report [Internet].

McDonagh MS, Selover D, Santa J, Lopez S.

Portland (OR): Oregon Health & Science University; 2005 Dec.

PMID:
20495995
[PubMed]
Books & Documents
12.
13.

[Anticholinergic treatment of overactive bladder syndrome. Is it all the same?].

Schneider T, Michel MC.

Urologe A. 2009 Mar;48(3):245-9. doi: 10.1007/s00120-008-1915-y. Review. German.

PMID:
19145428
[PubMed - indexed for MEDLINE]
14.

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D.

Eur Urol. 2008 Sep;54(3):543-62. doi: 10.1016/j.eururo.2008.06.047. Epub 2008 Jun 20. Review.

PMID:
18599186
[PubMed - indexed for MEDLINE]
15.

[The recommendations of the Polish Gynecologic Society regarding the use of darifenacin, selective muscarinic antagonists in the treatment of overactive bladder].

[No authors listed]

Ginekol Pol. 2007 Oct;78(10):815-20. Review. Polish. No abstract available.

PMID:
18200976
[PubMed - indexed for MEDLINE]
16.

Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.

Ko Y, Malone DC, Armstrong EP.

Pharmacotherapy. 2006 Dec;26(12):1694-702.

PMID:
17125433
[PubMed - indexed for MEDLINE]
17.

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.

Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003781. Review.

PMID:
17054185
[PubMed - indexed for MEDLINE]
18.

Darifenacin: another antimuscarinic for overactive bladder.

Guay DR.

Consult Pharm. 2005 May;20(5):424-31.

PMID:
16548640
[PubMed]
19.

Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.

Foote J, Glavind K, Kralidis G, Wyndaele JJ.

Eur Urol. 2005 Sep;48(3):471-7.

PMID:
15990219
[PubMed - indexed for MEDLINE]
20.

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.

Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K, Abrams P.

BJU Int. 2005 May;95(7):993-1001.

PMID:
15839920
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk